BU-NOT-SET

CONTACT US
What the new Drug Supply Chain Security Act (DSCSA) deadline means for the industry
  • Manufacturing
Eyes
Insight
Automating excipient selection using high-throughput screening
  • Drug substance
Eyes
Insight
Serialisation: is the industry ready?
  • Manufacturing
Eyes
Insight
Serialisation efforts must push ahead despite deadline extension
  • Manufacturing
Eyes
Insight
Metal coordinated pharmaceuticals: a new and promising technology
  • Drug product
Eyes
Insight
Optimising excipient selection
  • Drug product
Eyes
Insight
Serialisation stragglers: Industry concern for complacency
  • Manufacturing
Eyes
Insight
The race against the serialisation deadline
  • Manufacturing
Eyes
Insight
Why tomorrow is too late to start your serialisation preparations
  • Manufacturing
Eyes
Insight
Insight
  • Manufacturing
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
Brochure
  • Corporate
Recipharm 25 years
Fact sheet
  • Drug substance
API product list
Insight
  • Drug substance
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
Insight
  • Industry trends
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
Insight
  • Corporate
Women in leadership
Insight
  • Drug product
The state of the oral solid dose development and manufacturing market
Insight
  • Drug substance
Characterising APIs is Essential for Combo Drug Formulations
Insight
  • Analytical chemistry
Outsourcing stability testing